Locatie:
Berlijn
Startdatum:
14-april-2016
Einddatum:
17-april-2016
Don’t forget the early registration, January 18, for the ISN Nexus Symposium: Translational Immunology in Kidney Disease
ISN Nexus Symposium 2016:
April 14-17, 2016
Berlin, Germany
http://www.isnnexus.org/berlin/
About the symposium:
The format of ISN’s Nexus Symposia is uniquely tailored to focus on important new information and advances in a specific field of clinical relevance. These symposia strongly support the translational approach to disease management and have a clear objective of providing physicians with new insights and hands-on information that they can instantly apply. The ISN Nexus Symposia format allows for focused and in-depth discussions, networking and exchange of ideas among scientists and physicians who recognize the luxury of focusing on one specific topic that has strong clinical relevance. The translational nature of the content is amplified by an interspeciality approach, which provides an additional viewpoint and increased appreciation and understanding of the complexities of a disease. ISN Nexus Symposia bridge the gap between basic research and clinical practice and offer a profound focus on translational medicine and clinical application.
Drug development has dramatically improved disease outcomes in most medical disciplines, not so in nephrology. Despite enormous research efforts done by the basic science kidney research community only few drug targets finally could be successfully validated and developed into innovative drugs in clinical practice for the benefit of patients with kidney disease. There is an urgent need to improve translational science and successful drug development in the field of nephrology. It is part of the ISN’s mission to support this process.
We therefore announce the first ISN Nexus meeting on “Translational Immunology in Nephrology”. This Nexus meeting will bring together basic and clinical scientists as well as industry partners to present and discuss the future of immunosuppressive and immunomodulatory drugs in kidney disease. How to select the best molecular targets and to overcome the problems in translational research, the limitations in clinical trial design, and the implementation of novel drugs in clinical practice will be discussed. We therefore invite scientists and clinicians of the fields of nephrology, immunology, rheumatology, pharmacology as well as industry partners working on drug development programs for kidney diseases.
All information including preliminary program can be found on: http://www.isnnexus.org/berlin/
